Osteocrin and Vascular Complications

NCT ID: NCT05719740

Last Updated: 2023-02-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

90 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-02-28

Study Completion Date

2025-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study, we aimed to describe the role of bone-derived factor (osteocrin) in glucose metabolism, micro and macrovascular complications in diabetic patients. Thus, further investigations of the endocrine system through bone-derived hormones may provide as new perspectives on the prediction, prevention, and treatment of diabetes mellitus.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Diabetes mellitus (DM) remained the most common metabolic disorder worldwide occupying the 8th leading cause of death.\[1\] Defining new predictive biomarkers in diabetes would provide a window of opportunity for preventive and/or therapeutic interventions to prevent or delay the onset of irreversible long-term micro and or macro vascular complications. Progressive micro vascular vaso-degeneration is the major factor in progression of diabetic complications and contribute greatly to the increased mortality and morbidity. \[2\] Where Hemodynamic-mediated vascular injury was considered as one mechanism in the pathogenesis of diabetic nephropathy. \[3\] Bone disorders have been drawing attention as a novel diabetic complication, and diabetes is associated with an increased risk of osteoporotic fracture \[4-6\]. Bone is considered as an endocrine organ that influences various organs and tissues via the secretion of multiple bone derived hormones \[7-8\]. These endocrinal functions are, for example, glucose homeostasis \[9\], appetite control \[10\], fat deposition \[11\], skeletal muscle adaptation \[12\], male fertility \[13\], and cognition \[14\].

Therefore, these bone-derived hormones can become useful biomarkers for predicting the incidence of diabetes and the progression of diabetic complications. Osteocrin (OSTN), a bone-derived humoral factor, is a small secreted peptide cloned from bone and muscle complementary DNA (cDNA) libraries \[15\]. Osteocrin (Ostn) is secreted protein produced by cells of the osteoblast lineage that shows a well conserved homology with members of the natriuretic peptide (NP) family with prohormone-like characteristics \[17\]. To date, the exact role of Ostn has not been elucidated.

In this study, we aimed to describe the role of bone-derived factor (osteocrin) in glucose metabolism, micro and macrovascular complications in diabetic patients. Thus, further investigations of the endocrine system through bone-derived hormones may provide as new perspectives on the prediction, prevention, and treatment of diabetes mellitus.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Whether Osteocrin Levels Are Associated With Glycemic Control, Vascular Disorders in Diabetic Patients

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

45 patients in type 1 .DM

TYPE 1 DIABETES MELLITUS

osteocrin

Intervention Type DIAGNOSTIC_TEST

laboratory routine test

and 45 patients in type 2DM

TYPE 2 DIABETES MELLITUS

osteocrin

Intervention Type DIAGNOSTIC_TEST

laboratory routine test

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

osteocrin

laboratory routine test

Intervention Type DIAGNOSTIC_TEST

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

laboratory routine test

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients were diagnosed with diabetes mellitus according to American Diabetes Association
* Age range 20-70 years
* No apparent vascular abnormalities and Acute complications

Exclusion Criteria

* Patients are excluded for participation in the study if

* Patients had past history of cardiovascular events (heart failure or history of coronary artery disease),
* infections,
* aacute diabetic complications,
* diabetic patients on regular hemodialysis .
* acute illness, malignancy, or pregnancy.
Minimum Eligible Age

20 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assiut University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Walaa Soliman Hussein

principal investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

walaa soliman Hussien

Asyut, , Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

walaa S Hussien

Role: primary

01062637403

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Nephrologist

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Stretching and Diabetes
NCT06774105 COMPLETED NA
Recurrent Hypoglycemia in Type 1 Diabetes (Aim 2)
NCT04387422 ACTIVE_NOT_RECRUITING NA